Informed consent and palliative chemotherapy
Munday, Daniel and Maher, Jane, 1953- (2008) Informed consent and palliative chemotherapy. BMJ, Vol.337 . a868-a868. ISSN 0959-8138Full text not available from this repository.
Official URL: http://dx.doi.org/10.1136/bmj.a868
Better information is needed about prognosis and treatment, along with decision aids to help patients interpret it Informed consent is central to management decisions in modern medical practice. However, sharing information with patients about the value of chemotherapy for advanced metastatic cancer is highly challenging. In the linked study (doi: 10.1136/bmj.a752), Audrey and colleagues assess how much oncologists tell patients about the survival benefit of palliative chemotherapy during the first consultation after a diagnosis of metastatic colorectal cancer, pancreatic cancer, or non-small cell lung cancer.1 Although chemotherapeutic options have improved, life expectancy in people with metastatic cancer is often short, survival benefits of treatment may be modest, and the potential for unpleasant or life threatening side effects is high. Nevertheless, chemotherapy is increasingly given closer to the end of life,2 and patients are having to decide whether or not to have treatment at the same time as facing the harsh realities of dying.
|Item Type:||Journal Item|
|Subjects:||R Medicine > R Medicine (General)
R Medicine > RA Public aspects of medicine
|Divisions:||Faculty of Medicine > Warwick Medical School > Health Sciences
Faculty of Medicine > Warwick Medical School
|Library of Congress Subject Headings (LCSH):||Terminal care, Informed consent (Medical law), Cancer -- Palliative treatment, Patient education|
|Journal or Publication Title:||BMJ|
|Date:||31 July 2008|
Actions (login required)